ASCO 2023

Colorectal Cancer

7-year outcomes of PRODIGE 23 trial

Presented By

Prof. Thierry Conroy, Institut de Cancérologie de Lorraine, France

Trial

Phase 3, PRODIGE 23

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:04

Neoadjuvant chemotherapy may be viable option in locally advanced colon cancer

Presented By

Dr Lars Hendrik Jensen, University of Southern Denmark, Denmark

Trial

Phase 3, NeoCol

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 10:00

De-escalation of neoadjuvant treatment of locally advanced rectal cancer is non-inferior

Presented By

Dr Deborah Schrag, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, PROSPECT

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:58

Breast Cancer

SONIA: No survival benefit with first-line versus second-line CDK4/6 inhibition in metastatic breast cancer

Presented By

Prof. Gabe Sonke, Netherlands Cancer Institute, the Netherlands

Trial

Phase 3, SONIA

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:55

Adjuvant ribociclib improves invasive DFS in early breast cancer

Presented By

Prof. Dennis Slamon, David Geffen School of Medicine, CA, USA

Trial

Phase 3, NATALEE

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:52

Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer

Presented By

Dr Hanna Huebner, Erlangen University Hospital, Germany

Trial

Phase 2, GeparNuevo

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:49

Lung Cancer

Upper GI Cancer

Melanoma

Response-directed treatment personalisation in stage III melanoma

Presented By

Dr Irene Reijers, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, OpACIN-neo, PRADO

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:30

Prognostic and predictive biomarkers in patients with resected stage IIB/C melanoma

Presented By

Prof. Georgina Long, University of Sydney, Australia

Trial

Phase 3, CheckMate76K

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:27

GU Cancers

Combining PARP inhibition and androgen receptor-signalling inhibition improves radiographic progression-free survival in HRR-deficient mCRPC

Presented By

Prof. Karim Fizazi, Institute Gustave Roussy, France

Trial

Phase 3, TALAPRO-2

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:24

Erdafitinib outperforms chemotherapy in FGFR-altered advanced urothelial cancer

Presented By

Dr Yohann Loriot, Gustave Roussy Cancer Institute, France

Trial

Phase 3, THOR

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:20

Probiotic CBM588 seems to improve clinical effect cabozantinib/nivolumab in mRCC

Presented By

Dr Hedyeh Ebrahimi, Tehran University of Medical Sciences, Iran

Trial

Phase 1

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:11

Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups

Presented By

Dr Enrico Grande, MD Anderson Cancer Center, Spain

Trial

Phase 3, IMvigor130

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:08

Miscellaneous

ASCO Interviews

IMbrave050: Adjuvant atezolizumab plus bevacizumab provides landmark recurrence-free survival for HCC

Expert

Prof. Masatoshi Kudo, Kindai University, Japan

Conference

ASCO 2023

Type

Peer-reviewed article

17 July 2023 14:51

What can real-world evidence teach us about atezolizumab plus bevacizumab in HCC?

Expert

Dr Cha Len Lee, University of Toronto, Canada

Conference

ASCO 2023

Type

Peer-reviewed article

17 July 2023 14:47